Rebamipide does not interfere with the antitumor effect of radiotherapy or chemotherapy in human oral tumor-bearing nude mice

Abstract

Recent studies have shown that rebamipide, which suppresses reactive oxygen species, prevents chemoradiotherapy-induced oral mucositis in patients with head and neck cancers. However, anticancer action of radiotherapy and chemotherapy is believed to be partially associated with generation of reactive oxygen species. The aim of this study was to determine whether rebamipide interferes with the antitumor action of radiotherapy and chemotherapy. The effect of rebamipide on tumor cell growth was investigated using a human oral squamous carcinoma cell line, HSC-2, in vitro and in vivo. Rebamipide showed no significant effect on cell or tumor growth in HSC-2 tumor-bearing nude mice. Influences of rebamipide on the antitumor action of radiotherapy and of chemotherapy with cisplatin or docetaxel were investigated using the same animal model. In radiotherapy, the tumor was treated with 2.5 Gy of X-rays for 5 days, and rebamipide (300 mg/kg p.o.) was administered during irradiation periods. In chemotherapy, tumor-bearing mice were treated once with cisplatin (8 mg/kg, i.v.) or docetaxel (15 mg/kg i.v.) and rebamipide (300 mg/kg p.o.) was administered for 5 days following the antitumor drug treatment. Rebamipide did not interfere with the antitumor action of radiotherapy and chemotherapy.

Aberrant Expression of miR-362 Promotes Lung Cancer Metastasis through Downregulation of Sema3A

“…All animal experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals of FMMU. A lung cancer xenograft model was established by suspending 5 × 10 6 A549/A549 miR-362 knockout cells in 200 μ l of phosphate-buffered saline and subcutaneously inoculating the solution into the right flanks of nude mice [ 26 – 28 ]. When the tumor volume reached 100 mm 3 , the drug was administered.…”

Preparation and Evaluation of Rebamipide Colloidal Nanoparticles Obtained by Cogrinding in Ternary Ground Mixtures

“…Allopurinol has a good treatment effect on stomatitis; however, it interacts with fluorouracil, which decreases its anticancer effect, and it has been reported that there are restrictions to its administration [20,21]. On the other hand, RB can be administered in any case because there is no interaction with anticancer agents [22]. In addition, it has been reported that RB works effectively to treat stomatitis as a free radical scavenger, as an anti-inflammatory drug, and by inducing mucosal repair in phases I-IV [8,11,23].…”